Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine

References

• Amador ML, Oppenheimer D, Perea S et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res.64(24), 9139–9143 (2004).
   PubMed Web of Science ®Google Scholar
• Liu G, Gurubhagavatula S, Zhou W et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J.8(2), 129–138 (2008).
   PubMed Web of Science ®Google Scholar
• McKibbin T, Zhao W, Tagen M et al. Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib. Eur. J. Cancer46(11), 2045–2051 (2010).
   PubMed Web of Science ®Google Scholar
• Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J. Am. Acad. Dermatol.55(4), 657–670 (2006).
   PubMed Web of Science ®Google Scholar
• Saltz L, Rubin MS, Hochster H et al. Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Clin. Cancer Res.7, 3766S (2001) (Abstract 559).
   Web of Science ®Google Scholar
• Picard S, Titier K, Etienne G et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood109, 3496–3499 (2007).
   PubMed Web of Science ®Google Scholar
• Judson I, Ma P, Peng B et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumor: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother. Pharmacol.55, 379–386 (2005).
   PubMed Web of Science ®Google Scholar
• Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin. Pharmacokinet.44, 879–894 (2005).
   PubMed Web of Science ®Google Scholar
• Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood104(12), 3739–3745 (2004).
   PubMed Web of Science ®Google Scholar
• Hu S, Franke RM, Filipski KK et al. Interaction of imatinib with human organic ion carriers. Clin. Cancer Res.14(10), 3141–3148 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood104, 3739–3745 (2004).
   PubMed Web of Science ®Google Scholar
• Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE. hOCT 1 and resistance to imatinib. Blood106(3), 1133–1134 (2005).
   PubMed Web of Science ®Google Scholar
• Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin. Pharmacol. Ther.83(2), 258–264 (2008).
   PubMed Web of Science ®Google Scholar
• Kim DH, Sriharsha L, Xu W et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin. Cancer Res.15(14), 4750–4758 (2009).
   PubMed Web of Science ®Google Scholar
• Takahashi N, Miura M, Scott SA et al. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J. Hum. Genet.55(11), 731–737 (2010).
   PubMed Web of Science ®Google Scholar
• Hegedus T, Orfi L, Seprodi A, Váradi A, Sarkadi B, Kéri G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim. Biophys. Acta1587(2–3), 318–325 (2002).
   PubMed Web of Science ®Google Scholar
• Dulucq S, Bouchet S, Turcq B et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood112(5), 2024–2027 (2008).
   PubMed Web of Science ®Google Scholar
• Ni LN, Li JY, Miao KR, Qiao C, Zhang SJ, Qiu HR, Qian SX. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med. Oncol.28(1), 265–269 (2011).
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Barni R, le Coutre P et al. Role of α1 acid glycoprotein in the in vivo resistance of human BCR–ABL+ leukemic cells to the abl inhibitor STI571. J. Natl Cancer Inst.92(20), 1641–1650 (2000).
   PubMed Web of Science ®Google Scholar
• Gschwind HP, Pfaar U, Waldmeier F et al. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab. Dispos.33, 1503–1512 (2005).
   PubMed Web of Science ®Google Scholar
• Nebot N, Crettol S, D’Esposito F, Tattam B, Hibbs DE, Murray M. Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br. J. Pharmacol.161, 1059–1069 (2010).
   PubMed Web of Science ®Google Scholar
• Marsh S, Hoskins JM. Irinotecan pharmacogenomics. Pharmacogenomics11(7), 1003–1010 (2010).
   PubMed Web of Science ®Google Scholar
• Kim SR, Sai K, Tanaka-Kagawa T et al. Haplotypes and a novel defective allele of CES2 found in a Japanese population. Drug Metab. Dispos.35(10), 1865–1872 (2007).
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med.363(18), 1693–1703 (2010).
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304, 1497–1500 (2004).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350, 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Takano T, Ohe Y, Sakamoto H et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol.23(28), 6829–6837 (2005).
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med.363(9), 809–819 (2010).
   PubMed Web of Science ®Google Scholar
• Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene26, 6469–6487 (2007).
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science293, 876–880 (2001).
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood99(9), 3472–3475 (2002).
   PubMed Web of Science ®Google Scholar
• Choi YL, Soda M, Yamashita Y et al.; ALK Lung Cancer Study Group. EML4–ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med.363(18), 1734–1739 (2010).
   PubMed Web of Science ®Google Scholar
• Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res.61(12), 4744–4749 (2001).
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Rojo F, Ocaña A et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl Cancer Inst.99(8), 628–638 (2007).
   PubMed Web of Science ®Google Scholar
• Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol.14(3), 737–744 (1996).
   PubMed Web of Science ®Google Scholar
• Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene28(43), 3801–3813 (2009).
   PubMed Web of Science ®Google Scholar
• Hsu SC, Hung MC. Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J. Biol. Chem.282(14), 10432–10440 (2007).
   PubMed Web of Science ®Google Scholar
• Jacobs B, De Roock W, Piessevaux H et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol.27(30), 5068–5074 (2009).
   PubMed Web of Science ®Google Scholar
• Nagy P, Friedlander E, Tanner M et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res.65, 473–482 (2005).
   PubMed Web of Science ®Google Scholar
• Regales L, Balak MN, Gong Y et al. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS ONE2(8), E810 (2007).
   PubMed Web of Science ®Google Scholar
• Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res.65(23), 11118–11128 (2005).
   PubMed Web of Science ®Google Scholar
• Harris LN, You F, Schnitt SJ et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin. Cancer Res.13(4), 1198–1207 (2007).
   PubMed Web of Science ®Google Scholar
• Bean J, Brennan C, Shih JY et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl Acad. Sci. USA104(52), 20932–20937 (2007).
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med.359, 1757–1765 (2008).
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol.27, 2091–2096 (2009).
   PubMed Web of Science ®Google Scholar
• Johannessen CM, Boehm JS, Kim SY et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature468(7326), 968–972 (2010).
   PubMed Web of Science ®Google Scholar
• Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature468(7326), 973–977 (2010).
   PubMed Web of Science ®Google Scholar
• Loupakis F, Pollina L, Stasi I et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J. Clin. Oncol.27(16), 2622–2629 (2009).
   PubMed Web of Science ®Google Scholar
• Frattini M, Saletti P, Romagnani E et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br. J. Cancer97(8), 1139–1145 (2007).
   PubMed Web of Science ®Google Scholar
• Li FH, Shen L, Li ZH et al. Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer. World J. Gastroenterol.16(46), 5881–5888. (2010).
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat. Med.10(8), 789–799 (2004).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell144, 646–674 (2011).
   PubMed Web of Science ®Google Scholar
• Ding L, Ellis MJ, Li S et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature464(7291), 999–1005 (2010).
   PubMed Web of Science ®Google Scholar